JW Jungwo Pharmaceutical Completes Phase 1 Clinical Trial for Atopy New Drug
[Asia Economy Reporter Geum Bo-ryeong] JW Pharmaceutical announced on the 16th that it has completed the Phase 1 clinical trial of the atopic dermatitis new drug JW1601.
The clinical trial title is "A randomized, double-blind, placebo-controlled, single and multiple dose, dose-escalation Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of orally administered JW1601 in healthy Korean, Caucasian, and Japanese adults." The target disease is atopic dermatitis.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
JW Pharmaceutical stated, "Safety and excellent tolerability were confirmed in all dose groups for Koreans, Caucasians, and Japanese," adding, "Effective doses were identified through biomarker analysis."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
